458 Studies Now Enrolling
A Randomized, Double-blind, Multicenter, Active- controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression
A study for adults with depression using an investigational nasal spray in delaying the return of symptoms of depression
| Sponsor: | Janssen Research & Development, LLC |
| Enrolling: | Male and Female Patients |
| IRB Number: | 7404 |
| U.S. Govt. ID: | NCT02493868 |
| Contact: | Rain Rashid: 646-774-7594 / rr3110@cumc.columbia.edu |
Additional Study Information:
We are currently enrolling participants in a clinical research study to look at the effectiveness of an investigational medication (given as a nasal spray) in delaying the return of symptoms of depression in patients who have not responded to prior treatment with at least two antidepressants.
This study is closed
Do You Qualify?
| Are you experiencing persistent depression symptoms despite having taken at least two antidepressant medications? | Yes | No |
| Are you currently taking an antidepressant? | Yes | No |
| Have you been diagnosed with bipolar disorder or schizophrenia? | Yes | No |
| Have you attempted suicide in the past year? | Yes | No |
| Can you commit to frequent in-person appointments in NYC? | Yes | No |